Wells Fargo’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $147K | Sell |
19,004
-22,319
| -54% | -$163K | ﹤0.01% | 4891 |
|
|
2025
Q4 | $253K | Buy |
41,323
+8,088
| +24% | +$87.3K | ﹤0.01% | 4932 |
|
|
2025
Q3 | $613K | Buy |
33,235
+10,789
| +48% | +$173K | ﹤0.01% | 4149 |
|
|
2025
Q2 | $292K | Buy |
22,446
+3,818
| +20% | +$45.1K | ﹤0.01% | 4520 |
|
|
2025
Q1 | $197K | Sell |
18,628
-51,036
| -73% | -$810K | ﹤0.01% | 4713 |
|
|
2024
Q4 | $1.18M | Buy |
69,664
+7,785
| +13% | +$147K | ﹤0.01% | 3587 |
|
|
2024
Q3 | $1.44M | Sell |
61,879
-10,907
| -15% | -$233K | ﹤0.01% | 3306 |
|
|
2024
Q2 | $1.77M | Buy |
72,786
+1,128
| +2% | +$34.2K | ﹤0.01% | 3071 |
|
|
2024
Q1 | $2.42M | Sell |
71,658
-1,314
| -2% | -$46.6K | ﹤0.01% | 2821 |
|
|
2023
Q4 | $2.3M | Sell |
72,972
-37,743
| -34% | -$897K | ﹤0.01% | 2797 |
|
|
2023
Q3 | $2.83M | Sell |
110,715
-42,880
| -28% | -$1.32M | ﹤0.01% | 2531 |
|
|
2023
Q2 | $4.41M | Sell |
153,595
-7,043
| -4% | -$192K | ﹤0.01% | 2247 |
|
|
2023
Q1 | $3.85M | Buy |
160,638
+44,016
| +38% | +$790K | ﹤0.01% | 2329 |
|
|
2022
Q4 | $1.98M | Sell |
116,622
-67,666
| -37% | -$1.18M | ﹤0.01% | 2791 |
|
|
2022
Q3 | $2.73M | Buy |
184,288
+8,139
| +5% | +$137K | ﹤0.01% | 2467 |
|
|
2022
Q2 | $2.77M | Buy |
176,149
+19,530
| +12% | +$383K | ﹤0.01% | 2538 |
|
|
2022
Q1 | $4.22M | Buy |
156,619
+35,625
| +29% | +$909K | ﹤0.01% | 2598 |
|
|
2021
Q4 | $4.48M | Sell |
120,994
-18,463
| -13% | -$752K | ﹤0.01% | 2688 |
|
|
2021
Q3 | $6.66M | Buy |
139,457
+21,239
| +18% | +$952K | ﹤0.01% | 2570 |
|
|
2021
Q2 | $4M | Buy |
118,218
+10,086
| +9% | +$341K | ﹤0.01% | 3052 |
|
|
2021
Q1 | $4.47M | Sell |
108,132
-33,240
| -24% | -$1.98M | ﹤0.01% | 2964 |
|
|
2020
Q4 | $6.13M | Buy |
141,372
+65,321
| +86% | +$4.42M | ﹤0.01% | 2546 |
|
|
2020
Q3 | $3.26M | Buy |
76,051
+10,953
| +17% | +$544K | ﹤0.01% | 2908 |
|
|
2020
Q2 | $3.04M | Buy |
65,098
+49,239
| +310% | +$1.7M | ﹤0.01% | 2924 |
|
|
2020
Q1 | $216K | Buy |
15,859
+13,971
| +740% | +$179K | ﹤0.01% | 4633 |
|
|
2019
Q4 | $20K | Buy |
1,888
+1,037
| +122% | +$10.9K | ﹤0.01% | 5739 |
|
|
2019
Q3 | $9K | Sell |
851
-314
| -27% | -$3.39K | ﹤0.01% | 5950 |
|
|
2019
Q2 | $11K | Buy |
+1,165
| New | +$8.55K | ﹤0.01% | 5894 |
|
|
2018
Q4 | – | Sell |
-71
| Closed | -$1K | – | 6368 |
|
|
2018
Q3 | $1K | Hold |
71
| – | – | ﹤0.01% | 6271 |
|
|
2018
Q2 | $1K | Hold |
71
| – | – | ﹤0.01% | 6227 |
|
|
2018
Q1 | $0 | Hold |
71
| – | – | ﹤0.01% | 6346 |
|
|
2017
Q4 | $1K | Hold |
71
| – | – | ﹤0.01% | 6233 |
|
|
2017
Q3 | $1K | Hold |
71
| – | – | ﹤0.01% | 6200 |
|
|
2017
Q2 | $1K | Hold |
71
| – | – | ﹤0.01% | 6091 |
|
|
2017
Q1 | $1K | Hold |
71
| – | – | ﹤0.01% | 6205 |
|
|
2016
Q4 | $1K | Hold |
71
| – | – | ﹤0.01% | 6140 |
|
|
2016
Q3 | $1K | Hold |
71
| – | – | ﹤0.01% | 6092 |
|
|
2016
Q2 | $2K | Buy |
71
+35
| +97% | +$1.1K | ﹤0.01% | 5936 |
|
|
2016
Q1 | $1K | Hold |
36
| – | – | ﹤0.01% | 6078 |
|
|
2015
Q4 | $2K | Hold |
36
| – | – | ﹤0.01% | 6004 |
|
|
2015
Q3 | $2K | Hold |
36
| – | – | ﹤0.01% | 5973 |
|
|
2015
Q2 | $2K | Sell |
36
-738
| -95% | -$33.8K | ﹤0.01% | 6149 |
|
|
2015
Q1 | $30K | Sell |
774
-667
| -46% | -$29.3K | ﹤0.01% | 5219 |
|
|
2014
Q4 | $38K | Buy |
1,441
+1,305
| +960% | +$41.5K | ﹤0.01% | 5119 |
|
|
2014
Q3 | $15K | Sell |
136
-46
| -25% | -$5.99K | ﹤0.01% | 5416 |
|
|
2014
Q2 | $22K | Sell |
182
-216
| -54% | -$26.1K | ﹤0.01% | 5330 |
|
|
2014
Q1 | $51K | Buy |
+398
| New | +$59K | ﹤0.01% | 4926 |
|
Other funds holding ARCT
AIM
NAMA
VCM
VPM
Wells Fargo's ARCT Position: Q1 2026 in Review
Wells Fargo reduced its Arcturus Therapeutics (ARCT) stake by 54% in Q1 2026, selling an estimated $163K and leaving 19,004 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #4891.
Wells Fargo first reported a position in ARCT in Q1 2014 and has held it in 47 quarters since. The position peaked at $6.66M in Q3 2021. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.
- Wells Fargo held 19,004 shares of Arcturus Therapeutics worth $147K as of Q1 2026.
- Wells Fargo sold 22,319 Arcturus Therapeutics shares in Q1 2026, an estimated $163K.
- Arcturus Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4891 holding.
- Wells Fargo first reported a position in Arcturus Therapeutics in Q1 2014 and has held it in 47 quarters since.
- Wells Fargo's Arcturus Therapeutics position peaked at $6.66M in Q3 2021.
- 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.